Inclusion Criteria:

- Age ≥ 18 years

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

- Previously diagnosed with multiple myeloma

- Relapsed or refractory multiple myeloma with disease progression following one to
three prior treatment regimens

- Measurable multiple myeloma disease

Exclusion Criteria:

- Grade ≥ 2 peripheral neuropathy

- Use of corticosteroids within 21 days prior to Day 1

- Use of other anti-myeloma therapy within 21 days prior to Day 1

- Intolerance to bortezomib or compounds containing boron

- Life expectancy of < 12 weeks

- Current, recent, or planned participation in an experimental drug study

- Active malignancy other than multiple myeloma within 5 years before screening

- Prior treatment with bevacizumab

- Inadequately controlled hypertension

- Prior history of hypertensive crisis or hypertensive encephalopathy

- New York Heart Association (NYHA) Class II or greater congestive heart failure (CHF)

- Decreased left ventricular function at study entry

- History of myocardial infarction or unstable angina within 6 months prior to Day 1

- History of stroke or transient ischemic attack within 6 months prior to Day 1

- Significant vascular disease or recent peripheral arterial thrombosis within 6 months
prior to Day 1

- Evidence of bleeding diathesis or significant coagulopathy (in the absence of
therapeutic anticoagulation)

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to Day 1, or anticipation of need for major surgical procedure during the
course of the study

- Core biopsy or other minor surgical procedure, including placement of a vascular
access device within 7 days prior to Day 1

- History of abdominal fistula or gastrointestinal perforation within 6 months prior to
Day 1

- Serious, non-healing wound, active ulcer, or untreated bone fracture (for pathologic
bone fractures consistent with multiple myeloma, patients may be eligible if no
treatment is planned)

- Albuminuria

- Known hypersensitivity to any component of bevacizumab

- Pregnancy (positive pregnancy test) or lactation